MARKET

AKTX

AKTX

Akari
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.730
-0.070
-3.89%
Closed 16:00 09/18 EDT
OPEN
1.790
PREV CLOSE
1.800
HIGH
1.829
LOW
1.710
VOLUME
99.69K
TURNOVER
--
52 WEEK HIGH
2.790
52 WEEK LOW
0.8700
MARKET CAP
58.59M
P/E (TTM)
-1.9011
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average AKTX stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AKTX
Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. The Company’s lead product candidate, nomacopan inhibits both terminal complement activation and leukotriene B4, or LTB4. It inhibits terminal complement activation by tightly binding to C5 and preventing its cleavage and activation by complement.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Akari Therapeutics PLC (ADR) stock information, including NASDAQ:AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.